Robert C Smith

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients
    Robert C Smith
    Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatry Res 199:159-63. 2012
  2. ncbi Effects of nicotine nasal spray on cognitive function in schizophrenia
    Robert C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY, USA
    Neuropsychopharmacology 31:637-43. 2006
  3. ncbi Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia
    R C Smith
    Department of Psychiatry, New York University Medical School and Manhattan Psychiatric Center, New York, NY 11557 0316, USA
    Pharmacogenomics J 8:228-36. 2008
  4. ncbi Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study
    Robert C Smith
    Department of Psychiatry, NYU Medical School, Hewlett, NY 11557, USA
    J Clin Psychiatry 70:1501-13. 2009
  5. ncbi Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients
    Robert C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY 11557, USA
    Int J Neuropsychopharmacol 8:183-94. 2005
  6. ncbi Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study
    Robert C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY 11557, USA
    Schizophr Res 120:204-9. 2010
  7. ncbi Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder
    Robert C Smith
    Department of Psychiatry, New York University Medical School, NY 11557 0316, United States
    Schizophr Res 110:149-55. 2009
  8. ncbi Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia
    Robert C Smith
    Department of Psychiatry, New York University Medical School, New York, NY 11557 0316, USA
    Neuropsychopharmacology 27:479-97. 2002
  9. ncbi The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia
    R C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY 11557 0316, USA
    Int J Neuropsychopharmacol 4:239-50. 2001
  10. ncbi Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia
    Jean Pierre Lindenmayer
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Clin Schizophr Relat Psychoses 5:185-92. 2012

Detail Information

Publications17

  1. ncbi Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients
    Robert C Smith
    Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatry Res 199:159-63. 2012
    ..However, it is possible that different relationships may exist between appetite and weight changes induced by the medications in drug naive patients newly started on olanzapine or risperidone...
  2. ncbi Effects of nicotine nasal spray on cognitive function in schizophrenia
    Robert C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY, USA
    Neuropsychopharmacology 31:637-43. 2006
    ..Our results suggest that nicotine may modestly enhance attention and spatial working memory in schizophrenic patients who are cigarette smokers and have been abstinent overnight...
  3. ncbi Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia
    R C Smith
    Department of Psychiatry, New York University Medical School and Manhattan Psychiatric Center, New York, NY 11557 0316, USA
    Pharmacogenomics J 8:228-36. 2008
    ..These results provide a potential initial step toward a pharmacogenetic approach to selection of antipsychotic treatment which may help minimize the side effect of increases in serum lipids...
  4. ncbi Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study
    Robert C Smith
    Department of Psychiatry, NYU Medical School, Hewlett, NY 11557, USA
    J Clin Psychiatry 70:1501-13. 2009
    ..Randomized prospective studies of metabolic effects during treatment with these drugs may provide results that are more informative...
  5. ncbi Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients
    Robert C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY 11557, USA
    Int J Neuropsychopharmacol 8:183-94. 2005
    ....
  6. ncbi Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study
    Robert C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY 11557, USA
    Schizophr Res 120:204-9. 2010
    ..We present results of a randomized prospective study of lipid metabolism and metabolic syndrome in chronic schizophrenic patients using both fasting and post-prandial lipid measures...
  7. ncbi Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder
    Robert C Smith
    Department of Psychiatry, New York University Medical School, NY 11557 0316, United States
    Schizophr Res 110:149-55. 2009
    ..We present the first prospective quantitative data on the effects of varenicline on cognitive function, cigarette smoking, and psychopathology in a small sample of schizophrenic patients...
  8. ncbi Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia
    Robert C Smith
    Department of Psychiatry, New York University Medical School, New York, NY 11557 0316, USA
    Neuropsychopharmacology 27:479-97. 2002
    ..Nicotine nasal spray may modestly improve some selected aspects of cognitive function in schizophrenia...
  9. ncbi The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia
    R C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY 11557 0316, USA
    Int J Neuropsychopharmacol 4:239-50. 2001
    ..Neurocognitive changes were not correlated with changes in psychopathology as assessed by PANSS or SANS scores...
  10. ncbi Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia
    Jean Pierre Lindenmayer
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Clin Schizophr Relat Psychoses 5:185-92. 2012
    ....
  11. ncbi Hyperglycemia associated with the use of atypical antipsychotics
    J P Lindenmayer
    New York University School of Medicine, New York, USA
    J Clin Psychiatry 62:30-8. 2001
    ..However, it is difficult to statistically assess the true incidence of diabetes within each type of antipsychotic medication group with the exclusive dependence on available case studies and without proper epidemiologic research...
  12. ncbi Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study
    Robert C Smith
    Nathan Kline Institute for Psychiatric Research, NY, United States Department of Psychiatry NYU Medical School, New York, United States
    Schizophr Res 143:18-24. 2013
    ..Some studies also suggest possible pro-cognitive and antidepressant effects of pioglitazone. We studied the effects of pioglitazone on potential metabolic, symptomatic and cognitive benefits in schizophrenic patients treated with AP...
  13. ncbi Nonresponding schizophrenia: differentiation by neurological soft signs and neuropsychological tests
    R C Smith
    New York University Medical School, Manhattan Psychiatric Center, NY, USA
    Schizophr Bull 25:813-25. 1999
    ..Scores differentiating the two groups involved deficits influenced by both frontal and nonfrontal functioning. A predominance of negative symptoms in the current clinical picture was highly correlated with high NSS scores...
  14. ncbi Stability of neurological soft signs in chronically hospitalized schizophrenic patients
    R C Smith
    Department of Psychiatry, New York University Medical School, USA
    J Neuropsychiatry Clin Neurosci 11:91-6. 1999
    ..The findings suggest total NSS scores may have some characteristics of a trait-like feature in chronically hospitalized patients with schizophrenia...
  15. ncbi An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes
    A Zhubi
    Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, IL, USA
    Schizophr Res 111:115-22. 2009
    ..Hence, PBL studies may become useful to investigate a diagnostic epigenetic marker of SZ morbidity...
  16. ncbi Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms
    Robert C Smith
    Department of Medicine, Michigan State University, East Lansing, Michigan, USA
    Psychosom Med 67:123-9. 2005
    ..Our objective was to evaluate this use by determining the prevalence of DSM-IV somatoform and nonsomatoform disorders in patients with MUS proven by a gold standard chart review...
  17. ncbi A method for rating charts to identify and classify patients with medically unexplained symptoms
    Robert C Smith
    Department of Medicine, Michigan State University College of Human Medicine, East Lansing, Michigan, USA
    Psychother Psychosom 73:36-42. 2004
    ..As part of conducting a randomized control trial (RCT) to treat chronically high utilizing patients with medically unexplained symptoms (MUS), we developed the chart rating method reported here to identify and classify MUS subjects...